Avutometinib and Defactinib for diffuse stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two oral drugs, avutometinib and defactinib, for people with a specific type of stomach cancer called diffuse gastric cancer. The goal is to see if these drugs can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called diffuse, poorly cohesive, signet ring cell, or mixed type, or you have a CDH1 or RHOA gene change.
- You have already tried at least one chemotherapy that included a platinum drug and a fluoropyrimidine drug.
- You are 18 years or older.
- You are well enough to be up and about (ECOG score 0 or 1).
- Your heart, liver, kidneys, and blood counts are within acceptable ranges (your doctor will check).
- You are willing to have a tumor biopsy (or have fluid from your belly drained) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.